Watson launches authorized generic menopause drug
PARSIPPANY, N.J. — Watson has launched an authorized generic drug for treating postmenopausal women, the company said Friday.
Watson announced the launch of progesterone capsules in the 100-mg and 200-mg strengths, an authorized generic version of Abbott Labs’ Prometrium, under an agreement with Abbott. Abbott will manufacture the drug and supply it to Watson, which will market and distribute it and share profits. Other terms were not disclosed, the companies said.
The drug is used to prevent endometrial hyperplasia in postmenopausal women who have not undergone a hysterectomy and who are receiving conjugated estrogen tablets.
Prometrium had sales of about $198 million during the 12-month period ended in January, according to IMS Health.
Teva launches generic version of Prometrium
JERUSALEM — A generic drug maker has launched its version of an Abbott Labs drug.
Teva Pharmaceutical Industries said it launched progesterone capsules in the 100-mg and 200-mg strengths, a generic version of Prometrium.
Prometrium is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug also is indicated for use in secondary amenorrhea.
For the 12 months ended Jan. 31, Prometrium had sales of approximately $198 million, according to IMS Health data.
Independent Pharmacy Cooperative joins RxAlly
SUN PRAIRIE, Wis. — An organization representing independent pharmacies has joined a recently announced nationwide pharmacy network that aims to get patients to receive personalized care from their pharmacists.
The Independent Pharmacy Cooperative, which represents some 4,000 stores, announced that it had joined the RxAlly network, which includes more than 20,000 pharmacies across the country and whose membership includes independent pharmacy groups, regional chains and Walgreens. The network’s launch was announced Feb. 22 with the stated goal of improving patient health outcomes and reducing costs. American Associated Pharmacies, which represents about 2,000 independent pharmacies, also has joined.
"Independent pharmacies struggle every day to maintain their bottom line while trying to focus on their patients," IPC president and CEO Don Anderson said. "They must deal with increasing pressures from government regulations, reimbursements, payer sources and more while searching for ways to improve the outcomes of their patients and to control increase healthcare costs."